Arformoteroltartrate , 10mMinDMSO , 200815-49-2

CAS NO.：200815-49-2

Empirical Formula: C19H24N2O4.C4H6O6

Molecular Weight: 494.494

MDL number: MFCD07785830

EINECS: 200-589-5

PRODUCT Properties

• Melting point: 184°
• storage temp.: Refrigerator, Under Inert Atmosphere
• solubility: DMSO (Slightly, Sonicated), Methanol (Slightly, Heated, Sonicated)
• form: Solid
• color: White to Pale Brown
• InChIKey: FCSXYHUNDAXDRH-LFJODZMVNA-N
• SMILES: C1(NC=O)=C(C=CC([C@@H](O)CN[C@H](C)CC2C=CC(=CC=2)OC)=C1)O.[C@@H]([C@H](C(O)=O)O)(C(O)=O)O |&1:8,12,25,26,r|

Description and Uses

Aformoterol is the (R,R)-enantiomer of the β₂-adrenergic receptor (β₂-AR) agonist formoterol . It selectively binds to β₁- over β₂-ARs (K_ds = 2.9 and 113 nM, respectively) as well as β₃-adrenergic, B₂ bradykinin, neurokinin 1 (NK₁) and NK₂ receptors when used at concentrations up to 3 μM. Aformoterol induces cAMP accumulation in cultured human bronchial epithelial cells. Ex vivo, aformoterol (0.01-1,000 nM) induces dose-dependent relaxation of guinea pig tracheal strips precontracted with carbamoylcholine , ovalbumin, or histamine (pD₂s = 8.4, 9.5, and 9.5, respectively). In vivo, aformoterol reverses histamine- and ovalbumin-induced bronchoconstriction in guinea pigs (ED₅₀s = 1 and 40 nmol/kg, respectively). Formulations containing aformoterol have been used in the treatment of chronic obstructive pulmonary disease (COPD).

Anti-asthmatic and bronchodilator.

Safety

• Symbol(GHS): GHS08,GHS06
• Signal word: Danger
• Hazard statements: H302-H361-H334-H331-H351-H372
• Precautionary statements: P264-P270-P301+P312-P330-P501-P201-P202-P281-P308+P313-P405-P501-P260-P264-P270-P314-P501-P201-P202-P281-P308+P313-P405-P501-P261-P285-P304+P341-P342+P311-P501-P261-P271-P304+P340-P311-P321-P403+P233-P405-P501